Table 1.
Baseline clinical characteristics
| Total | M1a | M1b | |
|---|---|---|---|
| Number of patients | 20 | 5 | 15 |
| Age (y) median (range) | 59 (44–74) | 59 (49–74) | 57 (44–69) |
| Extent of disease | |||
| T1c | 1 (5%) | 0 (0%) | 1 (7%) |
| T2 | 5 (25%) | 1 (20%) | 4 (27%) |
| T3a | 4 (20%) | 1 (20%) | 3 (20%) |
| T3b | 7 (35%) | 1 (20%) | 6 (40%) |
| T4 | 3 (15%) | 2 (40%) | 1 (7%) |
| N1 (pelvic LN) | 11 (55%) | 5 (100%) | 6 (40%) |
| M1a (non-regional LN) | 7 (35%) | 5 (100%) | 2 (13%) |
| M1b | 15 (100%) | N/A | 15 (100%) |
| Number of bone metastases | |||
| 1–3 | 11 (55%) | N/A | 11 (73%*) |
| 4–5 | 2 (10%) | N/A | 2 (13%) |
| 6–7 | 2 (10%) | N/A | 2 (13%) |
| Gleason score | |||
| ≤7 | 3 (15%) | 0 (0%) | 3 (20%) |
| 8 | 4 (20%) | 0 (0%) | 4 (27%) |
| 9 or 10 | 13 (65%) | 5 (100%) | 8 (53%) |
| PSA at diagnosis | |||
| <20 | 8 (40%) | 0 (0%) | 8 (53%) |
| >20 | 12 (60%) | 5 (100%) | 7 (47%) |
| Primary ADT | |||
| LHRH agonist/antagonist | 20 (100%) | 5 (100%) | 15 (100%) |
| +Abiraterone | 9 (45%) | 2 (40%) | 7 (47%) |
| Duration of pre-RP ADT, months, median (range) | 4 (2–9) | 5 (2–8) | 3 (2–9) |
| Duration of primary ADT, months, median (range) | 11 (6–16) | 10 (7–12) | 11 (6–16) |
| 0–6 months | 1 (5%) | 0 (0%) | 1 (7%) |
| 7–12 months | 11 (55%) | 4 (80%) | 7 (47%) |
| 13–16 months | 4 (20%) | 0 (0%) | 4 (27%) |
| Continuous | 4 (20%) | 1 (20%) | 3 (20%) |
ADT, androgen deprivation therapy; LHRH, luteinizing hormone-releasing hormone; LN, lymph node; PSA, prostate-specific antigen; RP, radical prostatectomy. M1a = extrapelvic nodal disease; M1b = bone metastasis.
*
Initial bone scan not available for 1 patient; subsequent scan with 3 documented metastases.